Immunology Investor Event

Dupixent: Atopic Dermatitis Child <6yo Number of patients (thousands) Prevalence Treated Moderate-to-Severe 1,700 2,429 675 777 1,452 Uncontrolled 261 Moderate-to-Severe Biologics eligible 75 80 155 0 2,594 5,023 1,815 3,515 sanofi Assuming eligibility limited to severe uncontrolled in pediatric indications. EU Biologic eligible was derived from moderate-to-severe 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 4,500 5,000 5,500 Source: Sanofi analysis (1) Germany, France, Italy, Spain & United Kingdom. 5 Immunology Investor Event US Europe(1)

View entire presentation